Business Context and Reporting Period
This Form 8-K Current Report was filed by Vistagen Therapeutics, Inc. on July 29, 2026. The filing discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on personnel appointments and related compensatory arrangements.
Material Changes
- Board Appointment: The Board unanimously appointed Douglas J. Williamson, M.D., as a director effective July 29, 2026.
- Compensation Grant: Dr. Williamson received stock options to purchase 40,826 shares of common stock at an exercise price of $0.2433 per share.
- Vesting Schedule: The options vest in equal annual installments over three years, beginning one year after the appointment date.
- Legal Agreements: An Indemnification Agreement was executed to protect Dr. Williamson against liabilities arising from his director role.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of material risks and contingencies. It includes a reference to a press release (Exhibit 99.1) regarding the appointment, which is furnished but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the current share price and market capitalization to assess the value of the 40,826 options granted.
- Review the full text of the Indemnification Agreement (Exhibit 10.1) for specific liability caps or exclusions.
- Confirm Dr. Williamson's professional background and potential conflicts of interest not disclosed in this summary.
- Check the Company's latest 10-K or 10-Q for current cash reserves, as this 8-K does not provide liquidity data.